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ABSTRACT 
 
Objective: To review the antiplatelet and anticoagulant drugs currently used and to highlight the manage-
ment of patients with anticoagulant therapy undergoing minor and invasive oral and maxillofacial surgical 
procedures. Materials and methods: A systematic review of the literature on PubMed, Science Direct, 
Springer regarding anticoagulation therapy during oral surgery procedures from 1996 to 2020 was done. 
Data on the indications for anticoagulant treatment, the regimen of anticoagulation, bridging used, the pro-
cedure done, local hemostatic agents used, thromboembolic outcome, follow-up period and bleeding char-
acteristics were collected. Results: The thromboembolic risk due to withdrawal of oral anticoagulants out-
weighs the risk of bleeding and thus in majority of minor oral surgical procedures discontinuing the regimen 
is not recommended. Most of the bleeding complications can be controlled with local hemostatic measures. 
Major invasive oral and maxillofacial procedures with high risk patients warrants cessation of anticoagulant 
drugs with bridging therapy. The novel oral anticoagulants and newer antiplatelet agents has definite ad-
vantages over older main stay drugs especially warfarin and aspirin. 
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INTRODUCTION 
In our oral and maxillofacial practice, we come across 
lots of patients who are under anticoagulant and an-
tiplatelet therapy for different medical reasons. The 
anticoagulant therapy aims to prevent or reduce co-
agulation of blood, thereby prolonging the clotting 
time. Anticoagulant agents inhibit specific pathways 
of the coagulation cascade after the initial platelet ag-
gregation and finally leads to formation of fibrin.[1,2] 
Antiplatelet therapy decreases the ability of for-
mation of blood clots by interfering with the platelet 
activation process in primary hemostasis. These 
drugs reversibly or irreversibly inhibit the process 
involved in platelet activation resulting in decreased 
tendency of platelets to adhere to one another and to 
damaged endothelium of blood vessels. An antiplate-
let drug or platelet agglutination inhibitor or platelet 
aggregation inhibitor decrease platelet aggregation[3] 
and inhibit thrombus formation. They are effective in 
the arterial circulation, where anticoagulants have 
very little effect. 
Certain medical conditions, viz atherosclerosis and 
cardiac arrhythmias, can predispose individuals to 
the risk of a thrombosis or thromboembolism leading 
to heart attack, pulmonary embolism, or stroke. Anti-
coagulants and antiplatelet drugs play an important 
role in reducing these risks in patients with vascular, 
thromboembolic, or cardiac conditions like atrial fi-
brillation, a history of stroke or following surgical 
procedures such as heart valve replacements, cardiac 
stents, and joint replacements. Having said this the 
reduction in risk of thromboembolic events comes at 
the cost of an increased risk of bleeding, either spon-
taneously or associated with invasive procedures. 
The balance of these risks for an individual patient is 
the primary consideration in the management of pa-
tients undergoing minor or major oral and maxillofa-
cial surgery who are on anticoagulants or antiplatelet 
drugs.  
It has been noticed that a remarkable majority of oral 
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surgeons and dental practitioners still straightaway 
discontinue the patients antiplatelet or anticoagulant 
therapy anticipating bleeding episodes during and af-
ter the surgical procedure, thereby exposing the pa-
tient to a thromboembolic risk. Discontinuation of an-
ticoagulant or antiplatelet therapy carries significant 
risks of morbidity, sometimes with a fatal outcome, 
from thromboembolic complications[4]. To prevent 
these mishaps a comprehensive knowledge and 
treatment algorithm of anticoagulant and antiplatelet 
therapy is deemed necessary for the practicing sur-
geon. This article reviews the anticoagulant and an-
tiplatelet drugs which are currently in use today and 
evaluates the available evidence on the impact of an-
ticoagulant/antiplatelet medications on oral surgical 
treatment with emphasis on patient management is-
sues we come across in oral and maxillofacial prac-
tice. 
MATERIALS AND METHODS 
We have performed a systematic review of the litera-
ture on PubMed, ScienceDirect, Springer regarding 
anticoagulation during oral surgery procedures. The 
keywords used were: anticoagulation, anti-platelets, 
bridging, dental, oral maxillofacial surgery, dentistry. 
The range of the studies is from 1993 to 2020, From 
each study, we collected the following data: The indi-
cations for anticoagulant treatment, the regimen of 
anticoagulation, bridging used, the procedure done, 
local hemostatic agents used, thromboembolic out-
come, follow-up period and bleeding characteristics. 
RESULTS 
The thromboembolic risk due to withdrawal of oral 
anticoagulants outweighs the risk of bleeding and 
thus in majority of minor oral surgical procedures 
discontinuing the regimen is not recommended. Most 
of the bleeding complications can be controlled with 
local hemostatic measures. Major invasive oral and 
maxillofacial procedures with high risk patients war-
rants cessation of anticoagulant drugs with bridging 
therapy.  
DISCUSSION 
There are various derivatives and classes of anticoag-
ulant and antiplatelet drugs in use (Table 1). Antico-
agulants include - Vit K antagonists, Factor Xa inhibi-
tors, directly acting oral anticoagulants or previously 
called (Novel oral anticoagulants or Non-Vitamin K 
antagonists). Antiplatelets include - COX inhibitors, 
ADP receptor inhibitors, Phosphodiesterase inhibi-
tors, Adenosine reuptake inhibitors and Glycoprotein 
IIb/IIIa inhibitors. 
Anticoagulants  
Vit K antagonists viz Warfarin5 (Coumadin) is the 
most prescribed oral anticoagulant. Warfarin works 
by inhibiting the vitamin K-dependent clotting Fac-
tors II, VII, IX, X by binding to epoxide reductase, 
thereby reducing the available vitamin K. In addition 
to clotting factors, it also effects the coagulation reg-
ulatory factors protein C, protein S, and protein Z. In 
fact, warfarin has two functions – anticoagulant effect 
and antithrombotic effect.  
It takes at least 48 to 72 hours for Warfarin’s antico-
agulant effect to develop. Because of the delay in 
achieving antithrombotic effects, initial therapy with 
warfarin is combined with concomitant administra-
tion of a more rapidly acting parenteral anticoagulant 
(Heparin, LMWH, or Fondaparinux). Warfarin is ab-
sorbed rapidly from the gastrointestinal tract and it 
peaks in about 90 minutes after drug administration 
with a plasma half-life of 36 to 42 hours. These anti-
coagulants are used in treating patients with deep-
vein thrombosis (DVT), pulmonary embolism (PE) 
atrial fibrillation (AF), and mechanical prosthetic 
heart valves. Other examples are Acenocoumarol, 
Phenprocoumon, Atromentin, and Phenindione. War-
farin is administered in doses to achieve interna-
tional normalized ratio (INR) of 2.0 to 3.0 for most 
clinical indications (exception in patients with me-
chanical mitral heart valves where higher INR 2.5–3.5 
is needed. Warfarin has lot of food and drug interac-
tions. Alfalfa, Avocado, Spinach, Grapefruit, interact 
with anticoagulants. Antibiotics like Amoxicillin, 
Amoxicillin-clavulanate, Ciprofloxacin, Levofloxacin, 
Metronidazole, and Sulfamethoxazole increases the 
anticoagulant activity of warfarin whereas dicloxacil-
lin, nafcillin, rifampin, and rifapentine may decrease 
the anticoagulant activity. 
Factor Xa inhibitor: Heparin[6] was discovered 
by Jay McLean and William Henry Howell in 1916, 
although it did not enter clinical trials until 
1935. Heparin (Unfractionated Heparin) a naturally 
occurring glycosaminoglycan binds to the enzyme in-
hibitor antithrombin III (AT) via its pentasaccharide 
sequence, causing the activation through an increase 
in the flexibility of its reactive site loop. The activated 
AT then inactivates thrombin, factor Xa and other 
proteases. Prolongation of aPTT of 2 to 3 times is 
achieved, the other two categories of heparin are - 
low molecular weight heparin (LMWH), and ultra-
low-molecular weight heparin (ULMWH). 
Low molecular weight heparin (LMWH)[7]-Enoxapa-
rin (Lovenox), Dalteparin (Fragmin), Tinzaparin etc 
when compared to natural heparin consists of only 
short chains of polysaccharide. It is produced by con-
trolled depolymerization of unfractionated heparin. 
LMWH activates antithrombin III and subsequently 
inhibits factor Xa. LMWH has several benefits when 
compared to heparin. It has less frequent subcutane-
ous dosing than heparin viz once or twice daily sub-
cutaneous injection instead of intravenous infusion of 
high dose heparin. LMWH needs no monitoring of 
the APTT, has a smaller risk of bleeding and heparin 
induced thrombocytopenia and has less effect on 
thrombin. 
Synthetic pentasaccharide inhibitors of Factor Xa are 
Fondaparinux, Idraparinux and Idrabiotaparinux. 
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These are smaller molecules than LMWH. The most 
used is Fondaparinux[8]. (Arixtra) It is used as an al-
ternative to heparin or LMWH for initial treatment in 
those with established venous thromboembolism 
(VTE). Fondaparinux is contraindicated in patients 
with renal disorders since this medication is cleared 
unchanged by the kidneys. 
Direct /Novel Oral Anticoagulants[9] 
These are a new class of anticoagulant medications 
which were introduced after 2008 substituted for vit-
amin K antagonists and LMWH for relevant patients. 
DOACs have a rapid onset action, short half-lives, 
functions rapidly and effectively and allows easy re-
versal of anticoagulation effects. It needs less moni-
toring and dose adjustments, fewer drug interactions, 
no known dietary interactions, wider therapeutic in-
dex than warfarin. Given the short half-life of NOACs, 
these medications can be stopped within a shorter 
time period before any planned clinical procedure or 
surgical intervention without a need for a bridging 
agent which is not possible with warfarin. They can 
be grouped into Direct factor Xa inhibitors and Direct 
factor IIa inhibitors. 
Direct factor Xa inhibitors include Rivaroxaban, Apix-
aban, Edoxaban, and Betrixaban. They are getting 
popular because of the benefits mentioned above. 
Direct factor IIa inhibitors include Dabigatran, Bival-
irudin, Argatroban, Desirudin, although similar to the 
Xa inhibitors, target Factor IIa and cause direct inhi-
bition of thrombin. These have minimal drug interac-
tions and no food interactions, making them a popu-
lar alternative to warfarin. 
Rivaroxaban[10] has a half-life of 6-7 hours and 
reaches a maximum concentration within 4 hours. It 
is contraindicated in people with renal dysfunction. 
Edoxoban attains peak plasma concentration in 1 to 2 
hours. This medication should not be used in patients 
with increased creatinine clearance since it will im-
pair the efficacy. Edoxoban is mainly used for ex-
tended treatment of pulmonary embolism and deep 
vein thrombosis after the initial therapy. Apixaban is 
used for nonvalvular atrial fibrillation. It is used as an 
alternative to warfarin which can be taken orally and 
does not require monitoring by blood tests. 
Dabigatran (Pradaxa)[11] is a direct thrombin inhibi-
tor with half-life of 12–14 hours and has maximum 
anticoagulation of 2 to 3 hours, routine coagulation 
monitoring is not needed. Argatroban is adminis-
tered intravenously for management of acute Hepa-
rin induced thrombocytopenia (type II). It is elimi-
nated by the liver and is helpful in patients having re-
nal impairment and aPTT levels become normal in 2 
to 4 hours after discontinuation. 
Antiplatelet agents 
Antiplatelet agents are categorized according to their 
mode of action: Irreversible cyclooxygenase inhibi-
tors (COX) inhibitors, Adenosine diphosphate recep-
tor inhibitors, Phosphodiesterase inhibitors, Adeno-
sine reuptake inhibitors, Glycoprotein IIb/IIIa inhibi-
tors and Thromboxane inhibitors. (Figure 1). 
 
Figure 1: Classification of antiplatelet drugs 
Irreversible cyclooxygenase inhibitors (COX in-
hibitors) 
Aspirin[12] (acetylsalicylic acid-ASA) irreversibly in-
hibits prostaglandin H synthase (cyclooxygenase- 1) 
in platelets and megakaryocytes, and thereby blocks 
the formation of thromboxane A2. Low-dose ASA ir-
reversibly blocks thromboxane A2 in platelets, inhib-
iting platelet aggregation. This antithrombotic prop-
erty makes ASA useful for reducing cardiovascular as 
well as thrombotic events. It also inhibits both forms 
of cyclooxygenase isozymes (COX-1 and COX-2). 
Higher doses of ASA will also inhibit prostaglandin A2 
synthesis. The adverse effect of ASA is bleeding if it is 
clubbed with another antiplatelet or anticoagulant 
agent. ASA has also been shown to reduce the risk of 
colorectal and endometrial cancer. 
Adenosine diphosphate (ADP) inhibitors[13] 
P2Y12 receptors are Adenosine diphosphate (ADP) 
receptors expressed on the surface of thrombocytes, 
which can be blocked chemically. The overall effect of 
ADP to facilitate platelet aggregation and coagulation 
is very much reduced when ADP inhibitors are used. 
They are often prescribed in conjunction with aspirin, 
i.e. in dual antiplatelet therapy (DAPT) They can be 
classified as Thienopyridine and Cyclopentyltria-
zolopyrimidine (CPTP) group 
1. Thienopyridine: a.) Ticlopidine (Ticlid) b.) 
Clopidogrel (Plavix) c.) Prasugrel d.) Cangrelor 
2. Cyclopentyltriazolopyrimidine (CPTP): a.) Ti-
cagrelor (Brilinta) 
Clopidogrel[14] the thienopyridine derivative is me-
tabolised in the liver to active compounds which bind 
to the adenosine phosphate (ADP) receptor on plate-
lets and thereby inhibiting platelet activation. 
Clopidogrel reduces the risk of serious vascular 
events among high-risk patients when compared 
with aspirin. It is appropriate in patients who cannot 
tolerate aspirin or are at remarkably high risk of a 
vascular event. Addition of clopidogrel to aspirin re-
duces the risk of serious vascular events among pa-
tients with acute coronary syndromes and for patien- 
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-ts undergoing percutaneous coronary intervention. 
One negating factor is its cost when compared to as-
pirin. 
Prasugrel[15], a third-generation oral thienopyridine, 
is converted by CYP450 enzymes to its active metab-
olite. It binds irreversibly to P2Y12, inhibiting plate-
let function for the lifespan of the affected platelets. 
Prasugrel shows a more rapid onset of action than 
clopidogrel and it produces more effective platelet in-
hibition than clopidogrel. 
Cangrelor[16] is the latest approved I.V. non-thieno-
pyridine, reversible P2Y12 inhibiting agent which has 
various benefits over other drugs in this class. It 
shows a platelet inhibition greater than 90%. Within 
18-24 hours and without a loading dose Cangrelor 
achieves peak concentration levels. Cangrelor within 
60 min of stopping the infusion the platelet function 
recovers to normal. These impressive pharmacoki-
netic properties make cangrelor an agent for bridging 
of high-risk patients in the perioperative setting in 
contrast to the other antiplatelet drugs. Ticagrelor a 
CPTP has a binding site different from ADP, rendering 
it an allosteric antagonist, and its blockage is reversi-
ble. Its antiplatelet effect after 24 hours declines by 
50% and to 20% in 3 days. It has been shown to be 
superior to clopidogrel. 
Glycoprotein IIb/IIIa inhibitors or Intravenous 
antiplatelets[17] 
The platelet surface has abundant proteins i.e. the 
Glycoprotein IIb/IIIa (GpIIb/IIIa) receptors. These 
inhibitors block the adhesion of fibrinogen to the ac-
tivated platelet, preventing the building of interplate-
let bridges. Eventually adhesion of fibronectin and 
Von Willebrand factor, are inhibited. The major drugs 
in this group are Abciximab, Triofiban, and Eptifiba-
tide.  
Abciximab[18] irreversibly inhibits glycoprotein 
IIb/IIIa, leading to inhibition of platelet aggregation. 
The most common side effect is a higher risk of bleed-
ing and thrombocytopenia. A loading dose is neces-
sary to achieve a >80% inhibition. Its plasma life is 
short but has a biological activity of longer duration. 
Triofiban and Eptifibatide are synthetic GpIIb/IIIa in-
hibitors that reversibly bind which rapidly dissociate 
from the GpIIb/ IIIa receptor. The plasma concentra-
tion of these drugs determines the extent of platelet 
inhibition. 
Phosphodiesterase Inhibitors  
Cilostazol is a selective inhibitor of type 3 phos-
phodiesterase increasing cyclic adenosine mono-
phosphate (cAMP), leading to inhibition of platelet 
aggregation. In addition to this they also cause vaso-
dilation. 
Adenosine reuptake inhibitors[19]  
Dipyridamole inhibits the phosphodiesterase enzy- 
ymes that normally break down cAMP to ADP. Dipyr-
idamole inhibits the cellular reuptake of adeno-
sine into platelets, red blood cells, and endothelial 
cells, leading to increased extracellular concentra-
tions of adenosine. It is approved in combination with 
ASA for secondary prevention of stroke without in-
creasing the bleeding risk. 
In this article the authors have reviewed the admin-
istration of oral anticoagulant and antiplatelet drugs 
by various researchers in minor and major oral sur-
gery from 1994 to 2020.  
Farr, D. R., & Hare, A. R.[20] in 1994 concluded that the 
methods of thromboembolic prophylaxis used in oral 
and maxillofacial surgery were considered to provide 
a satisfactory degree of protection, in moderate and 
low risk patient groups. Ardekian, L., Gaspar, R., Peled 
et al[21] in 2000 concluded in their study that Low-
dose aspirin therapy should not be stopped before 
oral surgery. Local hemostasis is sufficient to control 
Table 1: Classes of Anticoagulant/ Antiplatelet drugs 
Antiplatelet Medications 
Aspirin 
Non-Steroidal Anti-inflammatory Drugs 
Thinopyridine derivatives (ticlopidine, clopidogrel) 
Platelet glycoprotein IIb/IIIa inhibitors (GPIIb/IIIa receptor antagonist) 
Unfractionated Heparin  
Low Molecular Weight Heparin  
Vitamin K Antagonists: Warfarin  
Thrombin (factor IIa) inhibitors 
Desirudin 
Lepirudin 
Bivalirudin 
Argatroban 
Factor Xa Inhibitors 
Fondaparinux 
Rivaroxaban 
Apixaban 
Edoxaban 
Thrombolytic and Fibrinolysis Medications 
Tissue plasminogen activator 
Streptokinase 
Urokinase 
Anistreplase 
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bleeding. Mehra, P., Cottrell, D. A., Bestgen et al22, in 
2000, analysed the use of a standard nomogram to 
help reduce level of anticoagulation preoperatively to 
effectively manage perioperative heparin therapy in 
chronically anticoagulated oral surgery patients who 
were at high risk for thromboembolism. They 
strongly recommended this nomogram which ac-
cording to them provided optimal therapeutic bene-
fit, decreased incidence of complications, and made 
hospitalization less costly and more comfortable for 
the patient.  
Campbell, J. H., Alvarado, F.& Murray, R. A. [23] in 2000 
performed a study to assess the extent of bleeding in 
anticoagulated patients undergoing minor oral sur-
gery procedures comparing with patients who stop 
their anticoagulation regimen before surgery and pa-
tients who have never been anticoagulated. Their 
data suggested that many patients can safely undergo 
routine outpatient oral surgical procedures without 
alteration of their regular therapeutic anticoagula-
tion regimens and without additional medical inter-
vention. Blinder, D., Manor, Y., Martinowitz, U., & 
Taicher[24] in 2001 evaluated the incidence of postop-
erative bleeding in patients treated with oral antico-
agulants who underwent dental extractions without 
interruption of the treatment and analysed the inci-
dence of postoperative bleeding according to Interna-
tional Normalised Ratio value (INR). They concluded 
their study stating that INR value at therapeutic doses 
does not significantly influence incidence of postop-
erative bleeding, therefore, dental extractions, ac-
cording to them, could be performed without modifi-
cation in oral anticoagulants treatment. Local hemo-
stasis with gelatine sponge and sutures appeared to 
sufficient to prevent postoperative bleeding.  
Scully, C., & Wolff, A.[25] in 2002 stated that the man-
agement of oral surgery procedures on patients 
treated with anticoagulants should be influenced by 
several factors: extent and urgency of surgery, labor-
atory values, treating physician’s recommendation, 
available facilities, dentist expertise, and patient’s 
oral, medical, and general condition. Bloomer, C. R.[26] 
presented a case report in 2004 on “Excessive Haem-
orrhage After Dental Extractions Using Low–Molecu-
lar-Weight Heparin (Lovenox) Anticoagulation Ther-
apy”. They found that patient’s postoperative bleed-
ing had many variables, and the exact cause couldn’t 
be accurately determined. LMWH (Low Molecular 
Weight Heparin) had been a culprit, according to 
them, in excessive haemorrhage with other medical 
therapy. Its therapeutic range had been reported as 
narrow. There had been several options for the man-
agement of dental surgery patients with mechanical 
prosthetic heart valves and patients with atrial fibril-
lation. They concluded that the outpatient use of 
LMWH for thromboprophylaxis is an alternative to 
hospitalization and heparinization. Risk and benefits 
must be carefully weighted and discussed with the 
patient, and accurate timing and accurate dosing of 
LMWH must be ensured.  
Beirne, O.R. [27] in 2005, provided an evidence to con-
tinue oral anticoagulant therapy for ambulatory oral 
surgery. They recommended that on the day of sur-
gery, the clinician should measure the patient’s INR 
to determine that it is within therapeutic range (2.0 
to 4.0). After the procedure, precautions should be 
taken to prevent postoperative bleeding. The patient 
should be given instructions to applying local pres-
sure to control bleeding and when to seek help. The 
postoperative medications for patients taking oral 
anticoagulants should be selected carefully. No cy-
clooxygenase (COX) I/II nonsteroidal anti-inflamma-
tory agents (NSAIDs) are appropriate. According to 
them, newer COX II selective agents had a better 
safety profile than COX I/II NSAIDs, but the newer 
COX II agents might also change the metabolism of 
warfarin as well as its effects. Low doses of aceta-
minophen are acceptable, but warfarin metabolism 
can also be altered by these agents. Patients can be 
given narcotic analgesics with no effect on anticoagu-
lation. Antibiotic prophylaxis is safe, but the 5- to 10-
day course of antibiotics postoperatively might alter 
intestinal bacterial flora, resulting in diminished vita-
min K levels and elevated INR. Warfarin’s metabolism 
is augmented by dicloxacillin and nafcillin, decreas-
ing the INR. They concluded that close postoperative 
monitoring of the INR for patients taking anticoagu-
lants who were prescribed antibiotics is needed.  
Cunningham, L. L., Brandt, M. T., & Aldridge, E. [28] in 
2006 proposed an article on perioperative treatment 
of the patient taking anticoagulation medication, 
summarised that typical treatment previously re-
quired prolonged hospital stays, complicated medica-
tion adjustments, multiple laboratory tests. It was in-
dicated that routine dental extractions could be com-
pleted with only local measures of haemostasis, with-
out cessation of anticoagulants and without the risk 
of thromboembolic events. Although, patients requir-
ing more invasive surgeries (trauma sufferers etc.), 
warfarin could be discontinued along-with bridging 
therapy with LMWH and maintaining INR between 
1.5-2.0. Patients who received antiplatelet therapy 
and required invasive OMF surgery could be treated 
with single-drug therapy with use of local measures 
of haemostasis or aspirin therapy alone if on two-
drug therapy.  
Sacco, R., Sacco, M., Carpenedo, M., & Moia, M. [29] in 
2006, carried out a randomised comparison of differ-
ent INR targets on patients undertaking oral antico-
agulants who came for oral surgical procedures. 
Their study concluded that using simple and inexpen-
sive measures for local hemostasis does not necessi-
tate reduction of Oral Anticoagulant Therapy (OAT) 
intensity in patients undergoing oral surgery. The 
adoption of this procedure might also prevent throm-
boembolic complications associated with subthera-
peutic INR values. Sacco, R., Sacco, M., Carpenedo, M., 
& Mannucci, P. M.[30] carried out a randomised com-
parison in 2007 to evaluate if it was possible to per 
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Table 2: Review of research studies 
Author 
(year) 
Design of 
study/re-
view 
Procedure Conclusion 
G. Borea 
(1993) 
Randomised 
study 
Dental extrac-
tion 
The anticoagulant treatment does not need to be withdrawn before 
oral surgery provided that local antifibrinolytic therapy is instituted. 
D. R. Farr 
(1994) 
Postal ques-
tionnaire  
OMFS consult-
ants question-
naire 
The methods of thromboembolic prophylaxis used in oral and maxil-
lofacial surgery were considered to provide a satisfactory degree of 
protection, in moderate and low risk patient groups. 
J. C. Lowry 
(1995) 
Retrospec-
tive survey 
Major OMF sur-
gery 
The incidence of DVT and PE in major maxillofacial surgery is low. 
Pushkar 
Mehra 
(2000) 
Prospective 
study 
Oral surgery 
The use of a standard nomogram to manage anticoagulation therapy 
in the oral surgery patient requiring heparinization is strongly recom-
mended. This provides optimal therapeutic benefit, decreases the in-
cidence of complications, and makes the hospitalization less costly 
and more comfortable for the patient. 
John H. 
Campbell 
(2000) 
Prospective 
study 
Minor OMF sur-
gery 
Patients can safely undergo routine outpatient oral surgical proce-
dures without alteration of their regular therapeutic anticoagulation 
regimens and without additional medical intervention. 
Leon Arde-
kian (2000) 
Randomised 
study 
Dental extrac-
tion 
Low-dose aspirin therapy should not be stopped before oral surgery. 
Local hemostasis is sufficient to control bleeding. 
D. Blinder 
(2001) 
Prospective 
study 
Dental extrac-
tion 
Dental extractions can be performed without modification of oral anti-
coagulant treatment. Local hemostasis with gelatine sponge and su-
tures appear to be sufficient to prevent postoperative bleeding. 
Crispian 
Scully 
(2002) 
Review Oral surgery 
The management of oral surgery procedures on patients treated with 
anticoagulants should be influenced by several factors: extent and ur-
gency of surgery, laboratory values, treating physician’s recommen-
dation, available facilities, dentist expertise, and patient’s oral, medi-
cal, and general condition. 
Fouad A. Al-
Belasy 
(2003) 
Prospective 
study 
Dental extrac-
tions 
Multiple extractions can be performed in patients taking oral anticoag-
ulant therapy without a change in their level of anticoagulation pro-
vided an efficient hemostatic measure is instituted. 
Emmanuel 
Soffer 
(2003) 
Review 
Effect of fibrin 
sealants on 
bone and perio-
dontal healing 
The “true autologous” 
platelet gels seem to be a better choice, but no experimental studies 
have been performed to show their clinical efficacy in bone and peri-
odontal healing. 
Charles R. 
Bloomer 
(2004) 
Case report 
Dental extrac-
tion 
The outpatient use of LMWH for thromboprophylaxis is an alternative 
to hospitalization and heparinization. Risk and benefits must be care-
fully weighted and discussed with the patient, and accurate timing and 
accurate dosing of LMWH must be ensured. 
O. Ross 
Beirne 
(2005) 
Review Ambulatory oral 
surgery 
It is preferable to continue the warfarin without interruption if major 
bleeding can be prevented. 
R. Sacco 
(2006) 
Randomised 
comparison 
Dental extrac-
tions 
Using simple and inexpensive measures for local hemostasis, it is not 
necessary to reduce OAT intensity in patients undergoing oral sur-
gery. 
Larry L. 
Cunning-
ham (2006) 
Review arti-
cle 
Oral surgery For patients needing invasive surgery (trauma), options include dis-
continuation of warfarin with heparin bridging, LMWH bridging, and 
maintaining INR between 1.5-2.0 
R. Sacco 
(2007) 
Prospective 
randomised 
study 
Minor OMF sur-
gery 
Using simple measures for local hemostasis, it is not necessary to 
reduce OAT in patients undergoing routine dental extractions. 
Michael T. 
Brennan 
(2007) 
Update and 
recommen-
dation 
Dental treat-
ments 
Recommended to continue low-dose aspirin therapy in routine dental 
extractions. 
Giovanni B. 
Ferrieri 
(2007) 
Retrospec-
tive study 
Minor OMF sur-
gery 
Comprehensive perioperative management protocol for oral surgery 
in patients taking oral anticoagulants can lead to safe and successful 
results with minimal complications. 
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Jay P. 
Malmquist 
(2008) 
Prospec-
tive study 
Minor OMF 
surgery 
HemCon Dental Dressing had been proven to be clinically effective he-
mostatic device that significantly shortened bleeding time following oral 
surgical procedures for all patients including those taking OAT. Also, 
these patients had improved surgical wound healing compared with 
those receiving control. 
Balasubrama-
nian Krishnan 
(2008) 
Prospec-
tive study 
Dental extrac-
tion 
Routine dental extractions can be safely performed in patients on long-
term antiplatelet medication with no interruption or alteration of their 
medication. 
Branislav V. 
Bajkin (2009) 
Random-
ised study 
Dental extrac-
tions 
In patients receiving OAT with an INR≤4.0, simple dental extractions 
can be performed safely without interruption or modification of OAT, us-
ing local hemostatic measures. 
Joel J. 
Napeñas 
(2009) 
Retro-
spective 
study 
Minor OMF 
surgery 
The frequency of oral bleeding complications after invasive dental pro-
cedures was low to negligible for patients who were receiving single or 
dual antiplatelet therapy. 
Carlos Madrid 
(2009) 
System-
atic review 
Dental im-
plants 
OAT discontinuation is not recommended for minor oral surgery, such 
as single tooth extraction or implant placement, provided that this does 
not involve autogenous bone grafts, extensive flaps or osteotomy prep-
arations extending outside the bony envelope. 
Denise E. van 
Diermen (2009) 
System-
atic review 
Dental treat-
ments 
It is not advisable to routinely discontinue antiplatelet and anticoagula-
tion medication before dental surgery. 
Aranza 
Cañigral (2010) 
Review 
Dental extrac-
tions 
The incorporation of platelet function tests increases the safety of oral 
surgery in elderly patients subjected to antiplatelet treatment, particu-
larly with acetylsalicylic acid and clopidogrel. 
Catherine H.L. 
(2010) 
Prospec-
tive study 
Minor OMF 
surgery 
Postoperative bleeding in patients on LMWH therapy alone is rare to 
non-existent, patients on warfarin and LMWH may be at increased risk 
of bleeding after invasive dental procedures. 
Christian Bacci 
(2011) 
Prospec-
tive case 
control 
study 
Dental im-
plant surgery 
Local hemostasis in dental implant surgery was able to prevent bleeding 
complications in patients on oral anticoagulants, allowing these surgical 
procedures to be performed on an outpatient basis. 
Yoshinari 
Morimoto 
(2012) 
Retro-
spective 
study 
Dental extrac-
tion 
Post of hemorrhage in tooth extraction occurs often in patients with an 
APTT of 57 sec or greater when continuous heparin infusion cannot be 
stopped. 
P. Maurer 
(2012) 
Retro-
spective 
study 
Major OMF 
surgery 
Patients receiving anticoagulants have a higher risk of orbital hemor-
rhage after orbital fracture and should be monitored closely. 
A. J. TAFUR 
(2012) 
Cohort 
study 
Peri-proce-
dural antico-
agulation 
management 
Factors predisposing to peri-procedural bleeding are primarily patient-
specific. Premature heparin re-initiation is an avoidable provider-
specific variable to consider. 
Branislav V. 
Bajkin (2012) 
Prospec-
tive study 
Dental extrac-
tion 
In patients receiving combined anticoagulant-aspirin therapy, simple 
tooth extractions can be performed safely without discontinuing either 
oral anticoagulant or antiplatelet therapy if their INRs are within thera-
peutic range and appropriate local hemostasis measures are provided. 
Wolfgang Eich-
horn (2012) 
Retro-
spective 
study 
Minor OMF 
surgery 
The results suggested that oral surgical procedures can be performed 
safely without alteration of the oral anticoagulant treatment. 
Alex C. Spy-
ropoulos 
(2012) 
Review Surgery (any) Most minor procedures, such as dental, dermatologic, and ophthalmo-
logic procedures, can be safely undergone while a patient is on warfarin 
within the specified target INR range and probably the NOACs in this 
setting. 
Denise. E. van 
Diermen (2013) 
System-
atic review 
Dental treat-
ments 
Do not interrupt oral antithrombotic medication, not even dual antiplate-
let therapy, in simple dental procedures. 
Joel J. 
Napenas 
(2013) 
Review Dental extrac-
tions, perio-
dontal prob-
ing 
There is no indication to alter or stop these drugs and local hemostatic 
measures are sufficient to control bleeding. 
Todd H. Baron 
(2013) 
Review Invasive pro-
cedures (any) 
For patients with coronary artery stents and those at high risk for cardi-
ovascular atherosclerotic events who are undergoing a low-risk proce-
dure, full-dose antiplatelet therapy should be continued. 
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Fábio Wildson 
Gurgel Costa 
(2013) 
System-
atic re-
view 
Minor OMF 
surgery 
Local hemostatic measures proved to be effective according to previously 
published studies. 
Thomas 
Vanassche 
(2014) 
Random-
ised con-
trol trial 
Peri-proce-
dural man-
agement 
Evidence suggests that NOAC treatment can be safely interrupted without 
bridging therapy. 
Lance A. Wil-
liams III (2014) 
Clinics ar-
ticle 
Review 
Although novel oral anticoagulants may simplify periprocedural anticoag-
ulation in the future, the management of novel oral anticoagulant–induced 
anticoagulation is currently difficult owing to the lack of validated reversal 
strategies and of laboratory tests that can accurately determine dose re-
sponses. 
Peer W. 
Kämmerer 
(2015) 
System-
atic re-
view 
Minor OMF 
surgery 
There is strong evidence that OAT patients undergoing minor oral surgery 
should not discontinue their medication in order to prevent thromboem-
bolic complications. 
Hamidreza 
Eftekharian 
(2015) 
Random-
ised clini-
cal trial 
Orthog-
nathic sur-
gery 
TXA is effective in reducing intra-operative blood loss in patients for whom 
substantial blood loss is anticipated. 
Branislav V. 
Bajkin (2015) 
Prospec-
tive study 
Dental ex-
tractions 
Dental extractions in patients who are highly anticoagulated (INR, 3.5-
4.2), as well as more extensive oral surgical procedures in patients who 
are therapeutically anticoagulated, can be performed safely without inter-
ruption or modification of the therapy. 
Paul R Daniels 
(2015) 
Review 
article 
Surgery 
(any) 
For patients on oral anticoagulants who need emergency surgery or who 
have postoperative bleeding, the management of those taking warfarin is 
relatively clear, and for patients taking a target specific oral anticoagulant, 
approaches are being defined. For these patients the advent of target spe-
cific oral anticoagulant antidotes offers promise. 
Michael J. Wahl 
(2015) 
Literature 
review 
Minor OMF 
surgery 
Warfarin anticoagulation should not be interrupted for most dental surgery 
R. Clemm 
(2016) 
Clinical 
compara-
tive study 
Dental im-
plants 
Anticoagulation therapy should be continued in patients undergoing im-
plant surgery and bone grafting procedures avoiding thromboembolic 
complications. Surgeons should always apply the most minimally invasive 
approach to reduce postoperative risks and be able to apply local hemo-
static measures in terms of a bleeding complication. 
Damian Dudek 
(2016) 
Single co-
hort pro-
spective 
study 
Dental ex-
traction 
Patients who received more than 2 dental extractions, who were under 
treatment with acenocoumarol, and who suffered from multiple cardiovas-
cular diseases were at high risk for bleeding events. 
C. Mauprivez 
(2016) 
Prospec-
tive obser-
vational 
study 
Dental ex-
traction 
Dental extractions can be performed safely in an outpatient facility, in pa-
tients treated with DOAC, by applying local hemostatic measures, without 
interrupting or modifying OAT. 
 
Branislav V. 
Bajkin (2012) 
Prospec-
tive study 
Dental ex-
traction 
In patients receiving combined anticoagulant-aspirin therapy, simple tooth 
extractions can be performed safely without discontinuing either oral anti-
coagulant or antiplatelet therapy if their INRs are within therapeutic range 
and appropriate local hemostasis measures are provided. 
Wolfgang Eich-
horn (2012) 
Retro-
spective 
study 
Minor OMF 
surgery 
The results suggested that oral surgical procedures can be performed 
safely without alteration of the oral anticoagulant treatment. 
Alex C. Spy-
ropoulos 
(2012) 
Review Surgery 
(any) 
Most minor procedures, such as dental, dermatologic, and ophthalmologic 
procedures, can be safely undergone while a patient is on warfarin within 
the specified target INR range and probably the NOACs in this setting. 
Denise. E. van 
Diermen (2013) 
System-
atic re-
view 
Dental 
treatments 
Do not interrupt oral antithrombotic medication, not even dual antiplatelet 
therapy, in simple dental procedures. 
Joel J. 
Napenas 
(2013) 
Review Dental ex-
tractions, 
periodontal 
probing 
There is no indication to alter or stop these drugs and local hemostatic 
measures are sufficient to control bleeding. 
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form oral surgery in patients on OAT, without stop-
ping the treatment. Their study showed that using 
simple measures for local hemostasis, it was not nec-
essary to reduce OAT in patients undergoing routine 
dental extractions.  
Ferrieri, G. B., Castiglioni, S., Carmagnola et al[31] in 
2007 evaluated bleeding complications associated 
with oral surgery patients performed on patients on 
oral anticoagulants without therapy modification or 
withdrawal following a standardised comprehensive 
perioperative management protocol. The findings 
from their study suggested that a comprehensive 
perioperative management protocol for oral surgery 
in patients on oral anticoagulants including thrombo-
embolic and bleeding risk assessment, atraumatic 
surgical technique, postoperative careful instruc-
tions, could lead to safe and successful results with 
minimal complications. Krishnan, B., Shenoy, N. A., & 
Alexander, M[32] in 2008 concluded that routine den-
tal extractions can be safely performed in patients on 
long-term antiplatelet medication with no interrup-
tion or alteration of their medication.  
Van Diermen, D. E., Aartman et al[33] in 2009 pub-
lished a study, named “Dental management of pa-
tients using antithrombotic drugs: critical appraisal 
Todd H. Baron 
(2013) 
Review 
Invasive 
proce-
dures 
(any) 
For patients with coronary artery stents and those at high risk for cardiovas-
cular atherosclerotic events who are undergoing a low-risk procedure, full-
dose antiplatelet therapy should be continued. 
Fábio Wildson 
Gurgel Costa 
(2013) 
System-
atic re-
view 
Minor 
OMF sur-
gery 
Local hemostatic measures proved to be effective according to previously 
published studies. 
Thomas 
Vanassche 
(2014) 
Random-
ised con-
trol trial 
Peri-pro-
cedural 
manage-
ment 
Evidence suggests that NOAC treatment can be safely interrupted without 
bridging therapy. 
Lance A. Wil-
liams III (2014) 
Clinics ar-
ticle 
Review 
Although novel oral anticoagulants may simplify periprocedural anticoagu-
lation in the future, the management of novel oral anticoagulant–induced 
anticoagulation is currently difficult owing to the lack of validated reversal 
strategies and of laboratory tests that can accurately determine dose re-
sponses. 
Peer W. 
Kämmerer 
(2015) 
System-
atic re-
view 
Minor 
OMF sur-
gery 
There is strong evidence that OAT patients undergoing minor oral surgery 
should not discontinue their medication in order to prevent thromboembolic 
complications. 
Hamidreza 
Eftekharian 
(2015) 
Random-
ised clini-
cal trial 
Orthog-
nathic 
surgery 
TXA is effective in reducing intra-operative blood loss in patients for whom 
substantial blood loss is anticipated. 
Branislav V. 
Bajkin (2015) 
Prospec-
tive study 
Dental ex-
tractions 
Dental extractions in patients who are highly anticoagulated (INR, 3.5-4.2), 
as well as more extensive oral surgical procedures in patients who are ther-
apeutically anticoagulated, can be performed safely without interruption or 
modification of the therapy. 
Paul R Daniels 
(2015) 
Review 
article 
Surgery 
(any) 
For patients on oral anticoagulants who need emergency surgery or who 
have postoperative bleeding, the management of those taking warfarin is 
relatively clear, and for patients taking a target specific oral anticoagulant, 
approaches are being defined. For these patients the advent of target spe-
cific oral anticoagulant antidotes offers promise. 
Michael J. 
Wahl (2015) 
Literature 
review 
Minor 
OMF sur-
gery 
Warfarin anticoagulation should not be interrupted for most dental surgery 
R. Clemm 
(2016) 
Clinical 
compara-
tive study 
Dental im-
plants 
Anticoagulation therapy should be continued in patients undergoing implant 
surgery and bone grafting procedures avoiding thromboembolic complica-
tions. Surgeons should always apply the most minimally invasive approach 
to reduce postoperative risks and be able to apply local hemostatic 
measures in terms of a bleeding complication. 
Damian Dudek 
(2016) 
Single co-
hort pro-
spective 
study 
Dental ex-
traction 
Patients who received more than 2 dental extractions, who were under 
treatment with acenocoumarol, and who suffered from multiple cardiovas-
cular diseases were at high risk for bleeding events. 
C. Mauprivez 
(2016) 
Prospec-
tive ob-
serva-
tional 
study 
Dental ex-
traction 
Dental extractions can be performed safely in an outpatient facility, in pa-
tients treated with DOAC, by applying local hemostatic measures, without 
interrupting or modifying OAT. 
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of existing guidelines”. The objectives were to iden-
tify guidelines available for management of dental in-
vasive procedures in patients on antithrombotic 
drugs, to assess their quality with the Appraisal of 
Guidelines for Research and Evaluation (AGREE) in-
strument, and to summarize their conclusions and 
recommendations. They concluded, with the help of 
the available literature that it is not advisable to rou-
tinely discontinue antiplatelet and anticoagulation 
medication before dental surgery. Bajkin, B. V., Popo-
vic, S. L., & Selakovic, S. D.[34] in 2009 concluded that 
in patients receiving OAT with an INR≤4.0, simple 
dental extractions can be performed safely without 
interruption or modification of OAT, using local he-
mostatic measures.  
Napeñas, J. J., Hong, C. H., Brennan et al[35] in 2009 
concluded that the frequency of oral bleeding compli-
cations after invasive dental procedures was low to 
negligible for patients who were receiving single or 
dual antiplatelet therapy. Bacci, C., Berengo, M., 
Favero et al[36] in 2011 evaluated the incidence of 
bleeding complications following surgical implant 
therapy in a group patient receiving oral anticoagu-
lant therapy (warfarin) without interruption or 
modifications to their therapy. They concluded that 
local hemostasis in dental implant surgery was able 
to prevent bleeding complications in patients on oral 
anticoagulants, allowing these surgical procedures to 
be performed on an outpatient basis. Maurer, P., Con-
rad-Hengerer, I., Hollstein et al[37] in 2012 concluded 
that patients receiving anticoagulants have a higher 
risk of orbital hemorrhage after orbital fracture and 
should be monitored closely.  
Dinkova, A., Kirova, D., & Delev, D. [38] in 2013 stated 
that INR values should be obtained within 24 hours 
before the dental procedure. For patients with INR in 
the therapeutic range 2-4 or below, therapy modifica-
tion is not needed for simple single dental extrac-
tions. More complicated and invasive oral surgical 
procedures for patients with an INR on the high end 
of the scale or greater than 3.5 should be referred to 
physician for dose adjustment or therapy alteration 
before invasive dental procedures. Bajkin, B. V., 
Vujkov et al[39] in 2015 assessed the incidence of post-
operative bleeding in patients who were highly anti-
coagulated and in patients who underwent extensive 
oral surgical procedures and who continued using 
oral anticoagulant therapy. They concluded that den-
tal extractions in patients who are highly anticoagu-
lated (INR, 3.5-4.2), as well as more extensive oral 
surgical procedures in patients who are therapeuti-
cally anticoagulated, can be performed safely without 
interruption or modification of the therapy.  
Wahl, M. J., Pinto et al[40] in 2015 concluded that war-
farin anticoagulation should not be interrupted for 
most dental surgeries Mauprivez, C., Khonsari et al[41] 
in 2016 compared the incidence of postoperative 
bleeding events after dental extractions between pa-
tients treated with direct oral anticoagulants (DO-
ACs) and those treated with vitamin K antagonists 
(VKAs) without withdrawal of oral anticoagulant 
therapy (OAT). They concluded that dental extrac-
tions can be performed safely in an outpatient facility, 
in patients treated with DOAC, by applying local he-
mostatic measures, without interrupting or modify-
ing OAT. Yoshikawa, H., Yoshida et al[42] in 2019 and 
Ockerman, A., Bornstein et al[43] in 2020, also con-
cluded that managing the outpatients on anticoagu-
lants do not necessarily invite the cessation of OAT. 
(Table 2) [*OAT- Oral anticoagulant therapy] 
The study of various researchers on anticoagulant 
and antiplatelet therapy brings the oral and maxillo-
facial surgeons to draw conclusion on various aspects 
of management of patients who are on different clas-
ses of these medication in different settings viz -War-
farin, Heparin, DOACs and antiplatelet drugs. 
For a patient who is taking warfarin or another vita-
min K antagonist, with an INR below 4, dental treat-
ment can be carried out without interrupting their 
anticoagulant medication. Ensure that the patient’s 
INR has been checked, ideally no more than 24 hours 
before the procedure. If the patient has a stable INR, 
checking the INR no more than 72 hours before is ac-
ceptable. If there is reason to believe that a test result 
obtained up to 72 hours before dental treatment may 
not reflect the current level, then the patient’s INR 
should be tested again no more than 24 hours before 
the dental procedure. If the patient’s INR is 4 or 
above, inform the patient’s general medical practi-
tioner or anticoagulation service and delay treatment 
until the patient’s INR has been reduced to less than 
4. The patient’s INR is below 4, treat according to the 
general advice for managing bleeding risk  without 
interrupting their anticoagulant. 
Discontinuation of any antithrombotic medicine be-
fore carrying out an invasive procedure may pose a 
risk to the patient and on the other hand may cause 
increased post-operative bleeding if continued. So, 
risk vs benefits must always be weighed before con-
tinuing/discontinuing the antithrombotic drug ther-
apy. (Table 3) 
A stepwise approach is followed to manage the pa-
tients on Vit K antagonists and NOACs, which consists 
of 4 basic norms[44] viz- Assessment of bleeding risks 
by addressing if the anticoagulant has to be stopped 
for the surgery or the procedure can be performed 
while the patient is on anticoagulation medication, 
Deciding on the duration of preoperative interrup-
tion of the antithrombotic agent, Assessment of pa-
tient’s risk of suffering a thromboembolic event if 
there’s a perioperative interruption of anticoagula-
tion therapy and finally the consideration of the need 
for bridging therapy. 
Thrombocytopenia, active malignancy, presence of a 
prosthetic mitral valve or a history of bleeding 
tendencies are considered as the main risk factors. for 
 V. Raj Kumar et al., (2020) Int. J. Oral & Facial. Surg., 1(2), 27-43 
© Rubatosis Publications | International Journal of Oral and Facial Surgery 37  
bleeding.[45] HAS-BLED score (Table 4) has been 
found to be useful in assessing potential of bleeding 
risk if bridging therapy is to be considered. 
Patients at high risk can be treated with UFH or 
LMWH. Bridging with LMWH or UFH is started 24 to 
48 hours after warfarin cessation to allow INR values 
to drift towards normal.[47] Patients too unstable to 
cease anticoagulant therapy–e.g. patients who had 
undergone prosthetic valve replacements require 
lifetime anticoagulant therapy. These patients are 
placed on IV heparin once warfarin is stopped. After 
stopping warfarin, heparin is administered in the 
dose of 10,000 IU subcutaneously twice daily for two 
days. On the third day, the morning dose of heparin is 
skipped, and the INR value estimated. If the INR value 
is 1.5 to 2 times the normal, dental extraction is per-
formed as a traumatically as possible. Heparin is rec-
ommended 6 to 8 hours after surgery if there is no 
bleeding and continued for 2 days until warfarin 
which is also recommended on the day of surgery, be-
comes effective once again before the patient dis-
charged. (Each hospital may have their own protocol 
regarding the dose of heparin e.g. 8,000 IU given sub-
cutaneously thrice daily.) 
Bleeding complications from most of the surgical 
techniques include hematoma formation, hemarthro-
ses and subcutaneous ecchymosis. Patients receiving 
heparin 4 days or longer should have platelet count 
measured.[48] Patients receiving 5000 IU of subcuta-
neous UFH twice daily for DVT prophylaxis are not 
contraindicated to interventional procedures and no 
delay is necessary between performing the proce-
dure and administration of subsequent subcutaneous 
UFH.[49,50] Patients receiving IV UFH infusions should 
be stopped 2 to 6 hours with documentation of a nor-
mal aPTT before any invasive oral and maxillofacial 
procedure. A 4hr interval is considered before discon-
tinuing heparin and performing certain interven-
tional procedures and a 2h interval before restarting 
the therapy and in traumatic interventional proce-
dures a 24-hr interval is considered. A 12hour delay 
is considered in patients receiving prophylactic dos-
ing of SC LMHW (either enoxaparin 40 mg SC daily or 
30 mg twice daily). [51] 
Those receiving therapeutic LMWH delay of 24 hours 
after the last LMWH injection is recommended by the 
2010 ASRA guidelines. Post-procedurally, once daily 
LMWH for prophylaxis can be administered 6 to 8 
hours later after confirmation of normal haemostasis. 
A second post procedural LMWH prophylaxis dose 
could occur 24 hours later.  
Invasive interventions or surgery should not be per-
formed for those on therapeutic doses of fondapari-
nux (5– 10 mg SC daily) due to the increased risk of 
hematoma formation.[52] Patients taking fondapari-
nux, scheduled for low-risk interventional proce-
dures, 2 half-life intervals are adequate before proce-
dure. In moderate- or high-risk interventional proce-
dures, considerations for 5 half-lives or a 3- to 4-day 
discontinuation interval for fondaparinux is recom-
mended. Fondaparinux can be resumed 24 hours af-
ter the procedure. Patients taking fondaparinux 
should discontinue it 72 to 96 hours before elective 
invasive surgery when treated with therapeutic 
doses (7.5 mg SC) and for 24 hours for those receiving 
prophylactic doses (e.g., 2.5 mg SC). [52] 
For a patient taking NOAC requires a dental proce-
dure which has a low risk of bleeding complications, 
treatment can be done without interrupting their an-
ticoagulant medication or a patient who is taking 
NOAC and requires a dental procedure with a higher 
risk of bleeding complications, advise them to miss  
(apixaban, dabigatran)/delay (rivaroxaban) their 
morning dose on the day of their dental treatment.  
The complication arising from NOAC interruption 
and its continual without interruption is not a major 
concern as it depends on the procedure involved and 
the individual patient. For rivaroxaban (taken once a 
day), the delayed morning dose may be taken 4 hours 
after hemostasis has been achieved. The next dose 
should be taken as usual the following morning. If the 
patient routinely takes their rivaroxaban in the even-
ing, they can take this at the usual time on the day of 
treatment as long as it is no earlier than 4 hours after 
hemostasis has been achieved. For apixaban or 
dabigatran (taken twice a day), having missed the 
morning dose, the patient should take their evening 
dose of NOAC at the usual time as long as it is no ear-
lier than 4 hours after hemostasis has been achieved. 
In high-risk interventional procedures in patients 
with Dabigatran 4- to 5-day discontinuation period is 
recommended except for those patients with end-
stage renal disease, where a 6-day delay is warranted. 
Patients on rivaroxaban should have the medication 
discontinued for 3 days and apixaban 3 to 5 days be-
fore intermediate- and high-risk interventional pro-
cedures.[53] Bridging therapy is not needed, since 
thrombotic risks are not increased significantly with 
NOAC medication interruption.[54] Coagulation test-
ing (APTT, PT) can’t quantify effects of NOACs. These 
tests only confirm the presence of these agents in the 
patient’s circulation. 
Reversal agent for Warfarin can be by Fresh Frozen 
Plasma (10-15ml/kg), slow vit K infusion (5-10 mg) 
in urgent and emergent cases. Prothrombin complex 
concentrate can also be used. Idarucizumab[55] has re-
cently been approved by the FDA for reversal of 
dabigatran. In dire emergency situations, administra-
tion of prothrombin complex concentrate, and re-
combinant factor VII can be used during life threaten-
ing bleeding scenarios. [56,57] 
Antiplatelet therapy reduces the incidence of arterial 
thrombotic events in the perioperative period. Dis-
continuation of antiplatelet agents predisposes the 
risk of myocardial infarction, stent thrombosis, and 
morbidity related to inflammatory-mediated re-
bound effects of platelet adhesion. 
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Elective surgery should be decided on an individual-
patient basis. Antiplatelet therapy and treatment for 
other co-morbidities should be assessed. The relative 
risks of a thromboembolic episode and bleeding 
should be seriously considered. Restarting of an-
tiplatelet therapy depends on various factors viz, pa-
tient’s cardiovascular risk profile, the bleeding risks 
associated with the particular operation, and the 
pharmacokinetics of each drug. 
For operations with a low bleeding risk antiplatelet 
therapy does not need to be interrupted. Many stud-
ies and reviews have been carried out which state 
that the antiplatelet treatment, especially for minor 
oral surgical procedures, can be continued.[58,59,60,61]  
In procedures with a high risk of bleeding, aspirin 
should be maintained and other antiplatelet sub-
stances should be discontinued much before surgery 
to allow the antiplatelet effect to wear off. In patients 
with a low risk of thromboembolic events who re-
quire surgery that carries a high risk of hemorrhage, 
antiplatelet therapy should be interrupted in the 
perioperative period. Proper and meticulous evalua-
tion of the bleeding should guide intra- and postoper-
ative therapeutic strategies.[62,63,64] In situations 
where there is a high chance of bleeding and with-
drawal of antiplatelet therapy carries a high risk of 
cardiovascular events, bridging of antiplatelet ther-
apy can be considered. Bridging therapies can be by 
using long-acting P2Y12 antagonists with a short-act-
ing anticoagulant or antiplatelet agent that can be dis-
continued shortly before surgery. More recently, 
Cangrelor has become a much-recommended drug 
because of its pharmacokinetic profile. (Table 6) 
Table 3: Warfarin dosing recommendations 
Proce-
dures 
Examples INR level Coumadin dosing 
Low risk 
Single extraction 
Soft tissue biopsy/excision of soft tissue lesion ≤1 
cm in diameter 
<3.5 
Local hemostatic 
measures 
No change 
Local hemostatic 
measures 
Medium 
risk 
Multiple extractions: ≤5 teeth 
Soft tissue biopsy/excision of soft tissue lesion 1–3 
cm in diameter 
Placement of 1–3 dental implants 
<3.0 
Local hemostatic 
measures 
Withhold 1-2 day prior 
Restart within 24 hr 
High risk 
Multiple extractions >5 teeth or 
surgical 
Open mandible fracture repair 
Soft tissue biopsy/excision of soft tissue lesion >3 cm 
Biopsy/excision of a hard tissue lesion 
Removal of maxillary and/or mandibular tori 
Placement of multiple dental implants: >3 implants 
<2.5 
Local hemostatic 
measures 
Withhold 2-4 day 
Restart within 24 hr 
Table 4: HAS-BLED Score 
 Condition Points 
H Hypertension: (uncontrolled, >160 mmHg systolic) 1 
A 
Abnormal renal function: Dialysis, transplant, Cr >2.26 mg/dL or >200 µmol/L 
Abnormal liver function: Cirrhosis or Bilirubin >2x Normal or AST/ALT/AP >3x Normal 
1 
1 
S Stroke: Prior history of stroke 1 
B Bleeding: Prior Major Bleeding or Predisposition to Bleeding 1 
L Labile INR: (Unstable/high INR), Time in Therapeutic Range < 60% 1 
E Elderly: Age > 65 years 1 
D 
Prior Alcohol or Drug Usage History (≥ 8 drinks/week) 
Medication Usage Predisposing to Bleeding: (Antiplatelet agents, NSAIDs) 
1 
1 
Table 5: CHADS2 and CHA2DS2-VASc -Risk stratification scores 
C-Congestive heart failure 1 1 
H-Hypertension 1 1 
A-Age≥75y 1 2 
D-Diabetes 1 1 
S-Stroke/TIA 2 2 
V-Vascular disease (prior MI, PAD, or aortic plaque) --- 1 
A-Age 65-74y --- 1 
S-Sex category (female sex) --- 1 
Maximum score 6 9 
Abbreviations: CHADS2 congestive heart failure, Hypertension, Age (>65=1 point; >75=2 points), Diabetes and Stroke/transient ischemic 
attack; CHA2DS2-VASc Congestive heart failure, Hypertension, Age >75y, Diabetes and Stroke/transient ischemic attack, Vascular disease 
Age 65-74y, Sex category; MI myocardial infarction; PAD peripheral artery disease; TIA transient ischemic attack. 
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In an event of bridging, aspirin should be continued, 
and the other oral agent stopped 5–7 days before sur-
gery. A short-acting i.v. agent should be started in less 
than 72 h after the discontinuation of dual antiplate-
let therapy. Four to six hours (1 hour for cangrelor) 
before surgery, the i.v. drug is discontinued, and it is 
restarted 6 h after surgery. The patient’s usual dual 
antiplatelet therapy is restarted when the risk of peri-
operative hemorrhage becomes negligible.[65,66,67] 
Antiplatelet drugs have hemorrhage as a common ad-
verse-effect. Management of significant hemorrhage 
is based on the administration of tranexamic acid, fi-
brinogen, factor XIII, desmopressin, platelets, and ac-
tivated factor VIIa. The cardioprotective benefit of an-
tiplatelet therapy far outweighs the potential risk of 
bleeding.[68] It is however found that the risk of hema-
toma formation is increased in orbital or skull base 
surgery in patients on antiplatelet therapy.  
CONCLUSION 
According to the current results of research minor 
oral surgical procedures can safely be carried out 
with the INR within the therapeutic range (2.0-4.0) 
supplemented by local haemostatic measures to con-
trol bleeding. Patients who have an INR greater than 
4.0 should not undergo any form of oral surgical pro-
cedure, without the clinicians advise. If more than 3 
teeth must be extracted then multiple visits will be 
required and the extractions may be planned to re-
move 2-3 teeth at a time, by quadrant, or one at a time 
in separate visits  
In invasive oral and maxillofacial surgery warfarin is 
generally stopped 5 days before the proposed proce-
dure. It is also recommended to continue warfarin 
therapy to aiming INR between 2-3 instead of resort-
ing to bridging therapy with LMWH. CHADS2 score 
can precisely determine whether bridging therapy 
needs to be initiated if anticoagulation interruption is 
considered for those taking warfarin. The decision to 
stop warfarin for 5 days versus bridging with LMWH 
depends on the time elapsed since a patient’s last in-
cident of venous thromboembolism/pulmonary em-
bolism. 
Recent studies have shown that the bleeding profile 
of the new oral anticoagulants (NOAC) is more fa-
vourable and predictable than that of warfarin be-
cause of their stable anticoagulant effects, lower risk 
of drug interaction and less monitoring making surgi-
cal management safer and easier with these class of 
medications. Their postoperative bleedings are mi-
nor, not life-threatening and can be very well be con-
trolled with local hemostatic measures. 
While performing invasive oral and maxillofacial pro-
cedures therapeutically using LMWH delay of 24 
hours after the last LMWH injection is recommended 
and if given prophylactically 12hrs delay is suggested. 
Invasive interventions or surgery should not be per-
formed for those on therapeutic doses of fondapari-
nux (5-10 mg SC daily) due to the increased risk of 
hematoma formation. 
For operations with a low bleeding risk, antiplatelet 
therapy does not need to be interrupted In proce-
dures with a high risk of bleeding, aspirin should be 
maintained and other antiplatelet substances discon-
tinued much before surgery to allow the antiplatelet 
effect to wear off. Whenever there is a high chance of 
bleeding and withdrawal of antiplatelet therapy car-
ries a high risk of cardiovascular events, bridging of 
antiplatelet therapy can be considered. 
Most of the patients consult oral and maxillofacial 
surgeon for extractions, complicated exodontia, im-
pacted tooth removal, trauma, pathologies including 
cysts and tumours, TMJ surgeries, Implant surgeries, 
cosmetic surgeries etc. Many of these patients as 
mentioned before in this article may be under antico-
agulant/antiplatelet therapy. The perioperative pe-
riod is associated with a significant prothrombotic 
risk because of the inflammatory response that arises 
due to surgery. This risk must be aptly balanced with 
Table 6: Grading of procedural risks related to antiplatelet therapy 
Proce-
dures 
Examples 
Antiplatelet 
therapy 
Dual Antiplatelet Therapy 
Low risk 
Single extraction 
Soft tissue biopsy/excision of soft tissue le-
sion ≤1cm in diameter 
N
o 
ch
an
ge
 
Lo
ca
l h
em
os
ta
tic
 m
ea
su
re
s 
No change 
Local hemostatic measures 
Medium 
risk 
Multiple extractions: ≤5 teeth 
Soft tissue biopsy/excision of soft tissue le-
sion 1-3 cm in diameter 
Placement of 1-3 dental implants 
Consider withdrawal of one of the 
drugs before procedure 
(depending on patient’s risk factors) 
Restart after hemostasis is achieved 
High risk 
Multiple extractions: >5 teeth 
Surgical extractions of impacted teeth (e.g., 
impacted wisdom teeth) 
Soft tissue biopsy/excision of soft tissue le-
sion >3cm 
Biopsy/excision of a hard tissue lesion 
Removal of maxillary and/or mandibular tori 
Placement of multiple dental implants: >3 im-
plants 
Withhold of one of the drugs before 
procedure, 
Restart after hemostasis is achieved 
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the likely event of hemorrhage in patients treated 
with antiplatelet or anticoagulant drugs. Both situa-
tions carry a significant burden of morbidity and 
mortality. So, it is of utmost importance that the Oral 
surgeon must possess an in-depth knowledge about 
the various anticoagulant and antiplatelet medica-
tions in current use, their pharmacokinetics, dosage, 
and its adverse effects while treating these patients. 
For rendering a better treatment and care its manda-
tory that the operating surgeons review the guide-
lines periodically. 
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